Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts

European Journal of Cancer

Volumn 40, Issue 8, 2004, Pages 1275-1281

  Balsari, A ^a   Tortoreto, M ^b   Besusso, D ^b   Petrangolini, G ^b   Sfondrini, L ^b   Maggi, R ^a   Menard S ^b   Pratesi, G ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumour therapy; Combined therapies; CpG oligodeoxynucleotide; Topotecan; Toxicity

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 12; OLIGODEOXYNUCLEOTIDE DERIVATIVE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; GROWTH CURVE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES; PROSTATIC NEOPLASMS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; WEIGHT LOSS;

EID: 1942424044     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.01.023     Document Type: Article

References (33)

1. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2:2002;748-759.
2. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760.
3. Akira S., Takeda K., Kaisho T. Toll-like receptors. critical proteins linking innate and acquired immunity Nat. Immunol. 2:2001;675-680.
4. Hemmi H., Takeuchi O., Kawai T.et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
5. Warren T.L., Dahle C.E., Weiner G.J. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin. Lymphoma. 1:2000;57-61.
6. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., Hammerling G.J. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CPG-containing oligodeoxynucleotides. J. Immunol. 167:2001;5247-5253.
7. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59:1999;5429-5432.
8. Sfondrini L., Besusso D., Rumio C., Rodolfo M., Ménard S., Balsari A. Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J. 16:2002;1749-1754.
9. Heckelsmiller K., Rall K., Beck S.et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169:2002;3892-3899.
10. Sfondrini L., Besusso D., Zoia M.T.et al. Absence of CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J. Immunol. 169:2002;151-158.
11. Macfarlane D.E., Manzel L., Krieg A.M. Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents. evidence for blockade of apoptosis at a distal signalling step Immunology. 91:1997;586-593.
12. D'Arpa P., Liu L.F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta. 989:1989;163-177.
13. Pratesi G., De Cesare M., Carenini N.et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin. Cancer Res. 8:2002;3904-3909.
14. Zuco V., Supino R., De Cesare M.et al. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem. Pharmacol. 65:2003;1281-1294.
15. Rothenberg M.L. Topoisomerase I inhibitors. review and update Ann. Oncol. 8:1997;837-855.
16. Lipford G.B., Sparwasser T., Bauer M.et al. Immunostimulatory DNA. sequence-dependent production of potentially harmful or useful cytokines Eur. J. Immunol. 27:1997;3420-3426.
17. United Kingdom Co-ordinating Committee on Cancer Res. (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (ed. 2). Br J Cancer. 77:1998;1-10.
18. Guardabasso V., Munson P.J., Rodbard D. EXPFIT. a program for simultaneous analysis of families of exponential decay curves Comput. Methods Programs Biomed. 27:1988;55-63.
19. Gramzinski R.A., Doolan D.L., Sedegah M., Davis H.L., Krieg A.M., Hoffman S.L. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. 69:2001;1643-1649.
20. Krug A., Towarowski A., Britsch S.et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31:2001;3026-3037.
21. Stacey K.J., Sweet M.J., Hume D.A. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157:1996;2116-2122.
22. Jin L., Raymond D.P., Crabtree T.D.et al. Enhanced murine macrophage TNF receptor shedding by cytosine-guanine sequences in oligodeoxynucleotides. J. Immunol. 165:2000;5153-5160.
23. Debatin K.M. Cytotoxic drugs, programmed cell death, and the immune system. defining new roles in an old play J. Natl. Cancer Inst. 89:1997;750-751.
24. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 139:2003;89-97.
25. Magnusson C., Vaux D.L. Signalling by CD95 and TNF receptors. not only life and death Immunol. Cell Biol. 77:1999;41-46.
26. Sparwasser T., Miethke T., Lipford G.et al. Macrophages sense pathogens via DNA motifs. induction of tumor necrosis factor-alpha-mediated shock Eur. J. Immunol. 27:1997;1671-1679.
27. Huang S.F., Kim S.J., Lee A.T.et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res. 62:2002;5720-5726.
28. Weigel B.J., Rodeberg D.A., Krieg A.M., Blazar B.R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9:2003;3105-3114.
29. Bruns C.J., Shinohara H., Harbison M.T.et al. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res. 60:2000;2-7.
30. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162:1999;2368-2374.
31. Bauer M., Redecke V., Ellwart J.W.et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol. 166:2001;5000-5007.
32. Pruijt J.F., Verzaal P., van Os R.et al. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. PNAS. 99:2002;6228-6233.
33. Laterveer L., Lindley I.J., Hamilton M.S., Willemze R., Fibbe W.E. Interleukin-8 induces rapid mobilisation of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood. 85:1995;2269-2275.